Breast cancer, Kisqali
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage Early Breast Cancer Trial
Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at the European Society for Medical Oncology (“ESMO”) Congress 2024.
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells.
Healthshots on MSN18h
Chemotherapy: Your guide to understanding this cancer treatment and side effects
Chemotherapy is one of the most-used cancer treatments. It uses chemicals that stops the growth of cancer cells in the body.
ThePrint on MSN1d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Researchers share new cancer treatments to offer hope for patients | Morning in America
Dr. Vivek Subbiah, drug development chief at the Sarah Cannon Research Institute, discusses medical advances to treat cancer ...
STAT8d
A new drug offers a rare option for brain cancer treatment — and inspires hopes for more
A new therapy approved by the FDA is one of the first major brain tumor breakthroughs in decades, say neuro-oncologists.
Cancer Therapy Advisor11d
Prostate Cancer Treatment Challenge: Which Drugs to Use First
A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
Triple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
Changes in chromosomes of cancer cells may increase their sensitivity to anti-cancer drugs
Two complementary studies from the Faculty of Medical and Health Sciences at Tel Aviv University, in collaboration with the ...
health.economictimes.indiatimes1d
Bone marrow cancer drug shows success in treatment of blood disorder, finds study
The New England Journal of Medicine published the trial results, which show that patients with HHT who were administered the ...